What is Harmony Biosciences Holdings, Inc.'s earnings per share (EPS)?

Harmony Biosciences Holdings, Inc. (HRMY) reported diluted earnings per share of $2.71 for fiscal year 2025. This represents a 8.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Harmony Biosciences Holdings, Inc. Financials

HRMY

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Harmony Biosciences Holdings, Inc. (HRMY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 78/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Harmony Biosciences Holdings, Inc. has an operating margin of 24.0%, meaning the company retains $24 of operating profit per $100 of revenue. This strong profitability earns a score of 76/100, reflecting efficient cost management and pricing power. This is down from 26.7% the prior year.

Growth

Harmony Biosciences Holdings, Inc.'s revenue surged 21.5% year-over-year to $868.5M, reflecting rapid business expansion. This strong growth earns a score of 69/100.

Leverage

Harmony Biosciences Holdings, Inc. carries a low D/E ratio of 0.17, meaning only $0.17 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.60, Harmony Biosciences Holdings, Inc. holds $3.60 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.

Cash Flow

100

Harmony Biosciences Holdings, Inc. converts 40.1% of revenue into free cash flow ($347.9M). This strong cash generation earns a score of 100/100.

Returns

Harmony Biosciences Holdings, Inc.'s ROE of 18.2% shows moderate profitability relative to equity, earning a score of 52/100. This is down from 22.1% the prior year.

Altman Z-Score Safe

4.42

Harmony Biosciences Holdings, Inc. scores 4.42, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.6B) relative to total liabilities ($401.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

5/9

Harmony Biosciences Holdings, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

2.19x

For every $1 of reported earnings, Harmony Biosciences Holdings, Inc. generates $2.19 in operating cash flow ($348.2M OCF vs $158.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

14.2x

Harmony Biosciences Holdings, Inc. earns $14.2 in operating income for every $1 of interest expense ($208.5M vs $14.6M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$868.5M

YoY+21.5%

5Y CAGR+40.3%

Harmony Biosciences Holdings, Inc. generated $868.5M in revenue in fiscal year 2025. This represents an increase of 21.5% from the prior year.

EBITDA

N/A

Net Income

$158.7M

YoY+9.1%

Harmony Biosciences Holdings, Inc. reported $158.7M in net income in fiscal year 2025. This represents an increase of 9.1% from the prior year.

EPS (Diluted)

$2.71

YoY+8.0%

Harmony Biosciences Holdings, Inc. earned $2.71 per diluted share (EPS) in fiscal year 2025. This represents an increase of 8.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$347.9M

YoY+59.1%

Harmony Biosciences Holdings, Inc. generated $347.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 59.1% from the prior year.

Cash & Debt

$752.5M

YoY+66.1%

5Y CAGR+26.9%

Harmony Biosciences Holdings, Inc. held $752.5M in cash against $143.7M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

58M

YoY+1.0%

5Y CAGR+0.3%

Harmony Biosciences Holdings, Inc. had 58M shares outstanding in fiscal year 2025. This represents an increase of 1.0% from the prior year.

Margins & Returns

Gross Margin

77.2%

YoY-0.9pp

5Y CAGR-5.5pp

Harmony Biosciences Holdings, Inc.'s gross margin was 77.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.9 percentage points from the prior year.

Operating Margin

24.0%

YoY-2.7pp

5Y CAGR+13.4pp

Harmony Biosciences Holdings, Inc.'s operating margin was 24.0% in fiscal year 2025, reflecting core business profitability. This is down 2.7 percentage points from the prior year.

Net Margin

18.3%

YoY-2.1pp

5Y CAGR+41.4pp

Harmony Biosciences Holdings, Inc.'s net profit margin was 18.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 2.1 percentage points from the prior year.

Return on Equity

18.2%

YoY-3.8pp

5Y CAGR+56.3pp

Harmony Biosciences Holdings, Inc.'s ROE was 18.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 3.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$189.6M

YoY+30.0%

5Y CAGR+57.7%

Harmony Biosciences Holdings, Inc. invested $189.6M in research and development in fiscal year 2025. This represents an increase of 30.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$310K

YoY-73.1%

5Y CAGR+174.2%

Harmony Biosciences Holdings, Inc. invested $310K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 73.1% from the prior year.

HRMY Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$868.5M+21.5%	$714.7M+22.8%	$582.0M+32.9%	$437.9M+43.4%	$305.4M+91.2%	$159.7M
Cost of Revenue	$198.3M+26.5%	$156.8M+29.3%	$121.2M+45.2%	$83.5M+50.4%	$55.5M+100.2%	$27.7M
Gross Profit	$670.1M+20.1%	$557.9M+21.1%	$460.8M+30.0%	$354.4M+41.8%	$249.9M+89.3%	$132.0M
R&D Expenses	$189.6M+30.0%	$145.8M+91.7%	$76.1M+7.3%	$70.9M+133.4%	$30.4M+56.1%	$19.4M
SG&A Expenses	$152.5M+38.2%	$110.4M+15.8%	$95.3M+13.4%	$84.0M+31.5%	$63.9M+60.8%	$39.7M
Operating Income	$208.5M+9.2%	$190.8M-0.6%	$192.0M+59.8%	$120.2M+37.3%	$87.5M+415.3%	$17.0M
Interest Expense	$14.6M-16.3%	$17.5M-26.4%	$23.8M+26.4%	$18.8M-22.3%	$24.2M-15.4%	$28.6M
Income Tax	$56.4M+21.7%	$46.3M+4.0%	$44.5M+158.0%	-$76.8M-2812.2%	$2.8M	N/A
Net Income	$158.7M+9.1%	$145.5M+12.9%	$128.9M-29.0%	$181.5M+424.5%	$34.6M+193.6%	-$36.9M
EPS (Diluted)	$2.71+8.0%	$2.51+17.8%	$2.13-28.3%	$2.97+412.1%	$0.58+123.4%	$-2.48

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$243.8M+1.8%	$239.5M+19.4%	$200.5M+8.5%	$184.7M-8.2%	$201.3M+8.2%	$186.0M+7.7%	$172.8M+11.8%	$154.6M
Cost of Revenue	$68.5M+14.9%	$59.6M+56.3%	$38.2M+19.3%	$32.0M-41.2%	$54.4M+27.2%	$42.8M+33.1%	$32.1M+17.0%	$27.5M
Gross Profit	$175.2M-2.5%	$179.8M+10.8%	$162.3M+6.3%	$152.7M+4.0%	$146.9M+2.5%	$143.3M+1.8%	$140.7M+10.6%	$127.1M
R&D Expenses	$49.9M-9.1%	$55.0M+9.6%	$50.2M+45.2%	$34.5M-0.4%	$34.7M+36.6%	$25.4M-60.1%	$63.6M+186.6%	$22.2M
SG&A Expenses	$57.6M+93.1%	$29.8M-12.1%	$33.9M+8.6%	$31.2M+8.2%	$28.9M+1.0%	$28.6M+5.0%	$27.2M+6.0%	$25.7M
Operating Income	$38.6M-41.1%	$65.5M+35.9%	$48.2M-14.3%	$56.2M+0.9%	$55.7M-9.7%	$61.7M+189.0%	$21.4M-59.0%	$52.0M
Interest Expense	$3.5M-2.0%	$3.6M-0.7%	$3.6M-5.0%	$3.8M-8.9%	$4.2M-3.2%	$4.3M-1.3%	$4.4M-2.9%	$4.5M
Income Tax	$18.3M+9.9%	$16.6M+68.6%	$9.9M-15.1%	$11.6M+73.9%	$6.7M-58.4%	$16.1M+59.1%	$10.1M-24.9%	$13.5M
Net Income	$22.5M-55.8%	$50.9M+27.9%	$39.8M-12.7%	$45.6M-7.9%	$49.5M+7.3%	$46.1M+297.7%	$11.6M-69.8%	$38.3M
EPS (Diluted)	N/A	$0.87+27.9%	$0.68-12.8%	$0.78	N/A	$0.79+295.0%	$0.20-70.1%	$0.67

HRMY Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.3B+27.3%	$999.2M+23.1%	$811.4M+20.4%	$673.9M+55.5%	$433.4M+1.5%	$427.1M
Current Assets	$907.0M+56.6%	$579.3M+28.4%	$451.1M+12.7%	$400.3M+40.7%	$284.4M+8.2%	$262.9M
Cash & Equivalents	$752.5M+66.1%	$453.0M+45.4%	$311.7M+27.8%	$243.8M+4.0%	$234.3M+2.5%	$228.6M
Inventory	$5.4M-25.6%	$7.2M+34.2%	$5.4M+24.8%	$4.3M-3.0%	$4.4M+15.9%	$3.8M
Accounts Receivable	$96.8M+16.6%	$83.0M+12.0%	$74.1M+35.4%	$54.7M+57.1%	$34.8M+57.1%	$22.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$401.4M+18.0%	$340.0M-1.3%	$344.5M+27.1%	$271.0M+9.8%	$246.9M-25.1%	$329.9M
Current Liabilities	$252.1M+44.0%	$175.1M+6.9%	$163.8M+107.6%	$78.9M+46.7%	$53.8M-60.0%	$134.5M
Long-Term Debt	$143.7M-11.9%	$163.0M-8.7%	$178.6M-5.8%	$189.6M-0.2%	$190.0M-2.2%	$194.3M
Total Equity	$870.2M+32.0%	$659.2M+41.1%	$467.0M+15.9%	$402.8M+116.0%	$186.5M+91.9%	$97.2M
Retained Earnings	$160.9M+7161.0%	$2.2M+101.5%	-$143.3M+47.3%	-$272.1M+40.0%	-$453.6M+7.1%	-$488.2M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.3B+5.2%	$1.2B+9.0%	$1.1B+5.0%	$1.1B+5.6%	$999.2M+7.7%	$928.1M+8.1%	$858.4M+1.3%	$847.0M
Current Assets	$907.0M+8.1%	$838.8M+21.3%	$691.4M+7.6%	$642.7M+11.0%	$579.3M+10.9%	$522.4M+14.0%	$458.3M-4.4%	$479.5M
Cash & Equivalents	$752.5M+16.3%	$647.0M+18.5%	$546.0M+11.7%	$489.0M+7.9%	$453.0M+16.9%	$387.4M+22.1%	$317.3M-4.7%	$333.0M
Inventory	$5.4M-22.2%	$6.9M+12.8%	$6.1M-4.4%	$6.4M-11.3%	$7.2M+4.1%	$6.9M+22.5%	$5.6M-3.7%	$5.9M
Accounts Receivable	$96.8M-3.8%	$100.7M+8.2%	$93.0M-12.3%	$106.0M+27.6%	$83.0M+1.9%	$81.5M-2.0%	$83.2M+4.3%	$79.7M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$401.4M+7.6%	$373.1M+11.4%	$334.9M0.0%	$335.0M-1.5%	$340.0M+2.6%	$331.3M+3.6%	$319.8M-3.6%	$331.6M
Current Liabilities	$252.1M+12.9%	$223.4M+24.0%	$180.1M+2.9%	$175.1M0.0%	$175.1M+8.6%	$161.3M+10.0%	$146.6M-5.0%	$154.3M
Long-Term Debt	$143.7M-3.3%	$148.5M-3.2%	$153.3M-3.1%	$158.2M-3.0%	$163.0M-2.9%	$167.8M-2.1%	$171.4M-2.0%	$175.0M
Total Equity	$870.2M+4.2%	$835.1M+8.0%	$773.1M+7.3%	$720.5M+9.3%	$659.2M+10.4%	$596.8M+10.8%	$538.6M+4.5%	$515.4M
Retained Earnings	$160.9M+16.2%	$138.4M+58.1%	$87.6M+83.3%	$47.8M+2056.0%	$2.2M+104.7%	-$47.3M+49.4%	-$93.4M+11.0%	-$104.9M

HRMY Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$348.2M+58.4%	$219.8M+0.2%	$219.4M+51.9%	$144.5M+46.6%	$98.6M+3401.7%	-$3.0M
Capital Expenditures	$310K-73.1%	$1.2M+269.6%	$312K+81.4%	$172K-42.3%	$298K+14800.0%	$2K
Free Cash Flow	$347.9M+59.1%	$218.7M-0.2%	$219.1M+51.8%	$144.3M+46.9%	$98.3M+3389.6%	-$3.0M
Investing Cash Flow	-$39.6M+41.2%	-$67.5M-45.3%	-$46.4M+67.3%	-$141.8M-41.4%	-$100.3M-4909.9%	-$2.0M
Financing Cash Flow	-$9.0M+17.7%	-$11.0M+89.6%	-$105.6M-1642.9%	$6.8M-7.8%	$7.4M-96.5%	$209.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$100.0M	N/A	N/A	$167K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$126.2M+16.0%	$108.7M+37.1%	$79.3M+133.4%	$34.0M-55.0%	$75.6M+7.2%	$70.5M+65.4%	$42.6M+36.9%	$31.1M
Capital Expenditures	$107K+50.7%	$71K+1675.0%	$4K-96.9%	$128K-75.0%	$513K+17000.0%	$3K-99.5%	$632K+12540.0%	$5K
Free Cash Flow	$126.0M+16.0%	$108.7M+37.0%	$79.3M+134.3%	$33.9M-54.9%	$75.0M+6.5%	$70.5M+67.9%	$42.0M+34.8%	$31.1M
Investing Cash Flow	-$17.6M-268.2%	-$4.8M+75.6%	-$19.6M-929.3%	$2.4M+132.9%	-$7.2M-1064.7%	$745K+101.4%	-$54.9M-786.8%	-$6.2M
Financing Cash Flow	-$3.0M-0.6%	-$3.0M-11.5%	-$2.7M-663.1%	-$352K+87.2%	-$2.7M-133.3%	-$1.2M+65.9%	-$3.4M+5.2%	-$3.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HRMY Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	77.2%-0.9pp	78.1%-1.1pp	79.2%-1.8pp	80.9%-0.9pp	81.8%-0.8pp	82.6%
Operating Margin	24.0%-2.7pp	26.7%-6.3pp	33.0%+5.5pp	27.5%-1.2pp	28.7%+18.0pp	10.6%
Net Margin	18.3%-2.1pp	20.4%-1.8pp	22.1%-19.3pp	41.4%+30.1pp	11.3%+34.5pp	-23.1%
Return on Equity	18.2%-3.8pp	22.1%-5.5pp	27.6%-17.5pp	45.1%+26.5pp	18.6%+56.6pp	-38.0%
Return on Assets	12.5%-2.1pp	14.6%-1.3pp	15.9%-11.0pp	26.9%+18.9pp	8.0%+16.6pp	-8.6%
Current Ratio	3.60+0.3	3.31+0.6	2.75-2.3	5.07-0.2	5.29+3.3	1.95
Debt-to-Equity	0.17-0.1	0.25-0.1	0.38-0.1	0.47-0.5	1.02-1.0	2.00
FCF Margin	40.1%+9.5pp	30.6%-7.1pp	37.6%+4.7pp	33.0%+0.8pp	32.2%+34.0pp	-1.9%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	71.9%-3.2pp	75.1%-5.9pp	81.0%-1.7pp	82.7%+9.7pp	73.0%-4.0pp	77.0%-4.4pp	81.4%-0.8pp	82.2%
Operating Margin	15.8%-11.5pp	27.4%+3.3pp	24.0%-6.4pp	30.4%+2.8pp	27.7%-5.5pp	33.2%+20.8pp	12.4%-21.3pp	33.7%
Net Margin	9.2%-12.0pp	21.2%+1.4pp	19.8%-4.8pp	24.7%+0.1pp	24.6%-0.2pp	24.8%+18.1pp	6.7%-18.1pp	24.8%
Return on Equity	2.6%-3.5pp	6.1%+0.9pp	5.1%-1.2pp	6.3%-1.2pp	7.5%-0.2pp	7.7%+5.6pp	2.1%-5.3pp	7.4%
Return on Assets	1.8%-2.4pp	4.2%+0.6pp	3.6%-0.7pp	4.3%-0.6pp	5.0%-0.0pp	5.0%+3.6pp	1.4%-3.2pp	4.5%
Current Ratio	3.60-0.2	3.75-0.1	3.84+0.2	3.67+0.4	3.31+0.1	3.24+0.1	3.13+0.0	3.11
Debt-to-Equity	0.17-0.0	0.18-0.0	0.20-0.0	0.22-0.0	0.25-0.0	0.28-0.0	0.32-0.0	0.34
FCF Margin	51.7%+6.3pp	45.4%+5.8pp	39.6%+21.2pp	18.3%-19.0pp	37.3%-0.6pp	37.9%+13.6pp	24.3%+4.2pp	20.1%

Similar Companies

Sarepta Therapeutics Inc SRPT

$2.4B

Immunocore Holdings Plc IMCR

$1.6B

Mesoblast MESO

$1.9B

Dyne Therapeutics, Inc. DYN

$3.1B

Mannkind MNKD

$770.3M

Frequently Asked Questions

What is Harmony Biosciences Holdings, Inc.'s annual revenue?

Harmony Biosciences Holdings, Inc. (HRMY) reported $868.5M in total revenue for fiscal year 2025. This represents a 21.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Harmony Biosciences Holdings, Inc.'s revenue growing?

Harmony Biosciences Holdings, Inc. (HRMY) revenue grew by 21.5% year-over-year, from $714.7M to $868.5M in fiscal year 2025.

Is Harmony Biosciences Holdings, Inc. profitable?

Yes, Harmony Biosciences Holdings, Inc. (HRMY) reported a net income of $158.7M in fiscal year 2025, with a net profit margin of 18.3%.

How much debt does Harmony Biosciences Holdings, Inc. have?

As of fiscal year 2025, Harmony Biosciences Holdings, Inc. (HRMY) had $752.5M in cash and equivalents against $143.7M in long-term debt.

What is Harmony Biosciences Holdings, Inc.'s gross margin?

Harmony Biosciences Holdings, Inc. (HRMY) had a gross margin of 77.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Harmony Biosciences Holdings, Inc.'s operating margin?

Harmony Biosciences Holdings, Inc. (HRMY) had an operating margin of 24.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Harmony Biosciences Holdings, Inc.'s net profit margin?

Harmony Biosciences Holdings, Inc. (HRMY) had a net profit margin of 18.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Harmony Biosciences Holdings, Inc.'s return on equity (ROE)?

Harmony Biosciences Holdings, Inc. (HRMY) has a return on equity of 18.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Harmony Biosciences Holdings, Inc.'s free cash flow?

Harmony Biosciences Holdings, Inc. (HRMY) generated $347.9M in free cash flow during fiscal year 2025. This represents a 59.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Harmony Biosciences Holdings, Inc.'s operating cash flow?

Harmony Biosciences Holdings, Inc. (HRMY) generated $348.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Harmony Biosciences Holdings, Inc.'s total assets?

Harmony Biosciences Holdings, Inc. (HRMY) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Harmony Biosciences Holdings, Inc.'s capital expenditures?

Harmony Biosciences Holdings, Inc. (HRMY) invested $310K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Harmony Biosciences Holdings, Inc. spend on research and development?

Harmony Biosciences Holdings, Inc. (HRMY) invested $189.6M in research and development during fiscal year 2025.

How many shares does Harmony Biosciences Holdings, Inc. have outstanding?

Harmony Biosciences Holdings, Inc. (HRMY) had 58M shares outstanding as of fiscal year 2025.

What is Harmony Biosciences Holdings, Inc.'s current ratio?

Harmony Biosciences Holdings, Inc. (HRMY) had a current ratio of 3.60 as of fiscal year 2025, which is generally considered healthy.

What is Harmony Biosciences Holdings, Inc.'s debt-to-equity ratio?

Harmony Biosciences Holdings, Inc. (HRMY) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Harmony Biosciences Holdings, Inc.'s return on assets (ROA)?

Harmony Biosciences Holdings, Inc. (HRMY) had a return on assets of 12.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Harmony Biosciences Holdings, Inc.'s Altman Z-Score?

Harmony Biosciences Holdings, Inc. (HRMY) has an Altman Z-Score of 4.42, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Harmony Biosciences Holdings, Inc.'s Piotroski F-Score?

Harmony Biosciences Holdings, Inc. (HRMY) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Harmony Biosciences Holdings, Inc.'s earnings high quality?

Harmony Biosciences Holdings, Inc. (HRMY) has an earnings quality ratio of 2.19x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Harmony Biosciences Holdings, Inc. cover its interest payments?

Harmony Biosciences Holdings, Inc. (HRMY) has an interest coverage ratio of 14.2x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Harmony Biosciences Holdings, Inc.?

Harmony Biosciences Holdings, Inc. (HRMY) scores 78 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.